During the past 15 years, several multiparameter genomic tests have entered mainstream care for patients with early breast cancer, with some being endorsed for use by authoritative guidelines groups (ASCO, National Institute for Health and Care Excellence).1,2 The predominant use of the tests is in the management of estrogen receptor (ER)–positive primary disease. The gene discussed is ESR1; the disease is breast carcinoma.